DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2011-06-28

Last Posted Date: 2017-06-26

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 1036

Registration Number: NCT01383421

A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis

Phase 3

Completed

Conditions: Secondary Hyperparathyroidism
End-Stage Renal Disease

Interventions: Drug: paricalcitol

First Posted Date: 2011-06-27

Last Posted Date: 2018-07-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 13

Registration Number: NCT01382212

Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: ABT-436
Drug: Matching Placebo

First Posted Date: 2011-06-27

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 51

Registration Number: NCT01380704

Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous

Completed

Conditions: Secondary Hyperparathyroidism
Chronic Kidney Disease

First Posted Date: 2011-06-07

Last Posted Date: 2014-08-01

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 265

Registration Number: NCT01368042

Locations: 🇬🇷
Site Reference ID/Investigator# 50442, Pylaia Thessaloniki, Greece
🇬🇷
Site Reference ID/Investigator# 53422, Volos, Greece
🇬🇷
Site Reference ID/Investigator# 77554, Thessaloniki, Greece

and more 8 locations

Phase 2 Chronic Low Back Pain Study

Phase 2

Completed

Conditions: Chronic Low Back Pain

Interventions: Drug: hydrocodone/acetaminophen extended release
Drug: Placebo

First Posted Date: 2011-06-03

Last Posted Date: 2014-01-29

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 168

Registration Number: NCT01364922

Locations: 🇺🇸
Site Reference ID/Investigator# 54877, Burbank, California, United States
🇺🇸
Site Reference ID/Investigator# 54881, Williamsville, New York, United States
🇺🇸
Site Reference ID/Investigator# 54863, Marion, Ohio, United States

and more 14 locations

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

Phase 2

Completed

Conditions: Chronic Kidney Disease
Diabetic Nephropathy

Interventions: Drug: Placebo
Drug: Atrasentan

First Posted Date: 2011-05-20

Last Posted Date: 2013-08-28

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 149

Registration Number: NCT01356849

Locations: 🇺🇸
Site Reference ID/Investigator# 45998, Los Angeles, California, United States
🇺🇸
Site Reference ID/Investigator# 46031, Pembroke Pines, Florida, United States
🇺🇸
Site Reference ID/Investigator# 46666, Chicago, Illinois, United States

and more 69 locations

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2011-05-03

Last Posted Date: 2017-04-13

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 2088

Registration Number: NCT01346488

Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2011-05-03

Last Posted Date: 2016-03-11

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 172

Registration Number: NCT01346501

A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain

Phase 2

Completed

Conditions: Diabetic Neuropathic Pain

Interventions: Drug: Placebo
Drug: pregabalin
Drug: ABT-639

First Posted Date: 2011-04-29

Last Posted Date: 2013-01-08

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 193

Registration Number: NCT01345045

Locations: 🇺🇸
Site Reference ID/Investigator# 51548, Dallas, Texas, United States
🇺🇸
Site Reference ID/Investigator# 51302, Omaha, Nebraska, United States
🇺🇸
Site Reference ID/Investigator# 52743, Portland, Oregon, United States

and more 32 locations

Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism

Phase 3

Completed

Conditions: Secondary Hyperparathyroidism
Hemodialysis

Interventions: Drug: paricalcitol
Drug: maxacalcitol
Drug: maxacalcitol placebo
Drug: paricalcitol placebo

First Posted Date: 2011-04-26

Last Posted Date: 2013-06-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 255

Registration Number: NCT01341782

Locations: 🇯🇵
Site Reference ID/Investigator# 53485, Aichi, Japan
🇯🇵
Site Reference ID/Investigator# 54387, Sakai, Japan
🇯🇵
Site Reference ID/Investigator# 52748, Osaka, Japan

and more 42 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy